IN VITRO DRUG RESISTANCE IN CHILDHOOD MATURE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
DOI:
https://doi.org/10.12775/MBS.2014.018Keywords
B-ALL, acute B-cell leukemia, in vitro drug resistance, childrenAbstract
B a c k g r o u n d . Mature B-cell acute lymphoblastic leukemia (B-ALL) is a rare type of leukemia in children and counts for 1-2% of all leukemia cases. Pediatric B-ALL is treated according to protocols for non-Hodgkin lymphomas. O b j e c t i v e . The aim of the study was to analyze the in vitro drug resistance in children with B-ALL compared to ALL with other phenotypes. M a t e r i a l a n d m e t h o d s . A total number of 15 children with B-ALL (6 girls and 9 boys, median age 8 years, range 1.9-15 years) were included into the analysis. The in vitro drug resistance tests on leukemic cells were performed by means of the MTT assay. The results of B-ALL patients were compared to those obtained in patients with pre- B/common ALL (479 cases), pro-B-ALL (31cases) and T-ALL (87 cases). Results: B-ALL cells were more resistant than pre-B/common-ALL cells to dexamethasone and idarubicin. In comparison to pro-B-ALL phenotype, B-ALL blasts were more resistant to idarubicin and more sensitive to treosulfan. No significant differences were found in the in vitro drug resistance between B-ALL and T-ALL. Blasts of T-ALL were more resistant than pre-B/common-ALL cells to most of tested drugs. Conclusion: From the clinical point of view, B-ALL cells have similar in vitro drug sensitivity when compared to T-ALL, and higher drug resistance to dexamethasone than pre-B/common-ALL.
References
Balwierz W. Ostra białaczka szpikowa. In: Chybicka A, Sawicz-Birkowska K (eds): Onkologia i hematologia dziecięca, Edition Warszawa: Wydawnictwo Lekarskie PZWL 2008; 220-242.
Hołowiecki J. Białaczki ostre. In: Dmoszyńska A, Robak T (eds): Podstawy hematologii, Edition Lublin: Czelej 2008; 251-288.
Niemeyer C, Sallan S. Acute lymphoblastic leukemia. In: Nathan D, Oski F (eds): Hematology of Infancy and Childhood 4th Edition, Edition Philadelphia: W. B. Saunders Company 1992; 1249-1287.
Farber S, Diamond L, Mercer R. Temporary remission in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948; 238: 788-793. DOI: http://dx.doi.org/10.3322/canjclin.24.5.297
Pieters R, Huismans DR, Leyva A, Veerman AJ. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988; 41: 323-332.
Pieters R, Kaspers GJ, van Wering ER et al. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia 1993; 7: 392-397.
Styczyński J, Kołodziej B, Rafińska B et al. Skojarzony profil oporności in vitro na cytostatyki w ostrej białaczce limfoblastycznej u dzieci de novo i we wznowie: związek z cyklem komórkowym i rearanżacjami genów. Współcz Onkol 2007; 11: 367-375.
Wysocki M, Styczyński J, Dębski R et al. Drug resistance profile in childhood acute lymphoblastic leukemia on diagnosis and at relapse with respect to percentile values. Acta Haematol Pol 2002; 33: 341-349.
Szczepanek J, Pogorzała M, Konatkowska B et al. Differential ex vivo activity of bortezomib in newly diagnosed paediatric acute lymphoblastic and myeloblastic leukaemia. Anticancer Res 2010; 30: 2119-2124.
Styczyński J. Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol, 2007; 8: 59-75.
Kuryło-Rafińska B, Kołodziej B, Kubicka M, Wysocki M, Styczyński J. Differential ex vivo drug resistance profile in first and subsequent relapsed childhood acute myeloid leukemia in comparison to initial diagnosis. Med Biol Sci, 2012; 26: 47-52.
Styczynski J, Wysocki M. Ex vivo drug resistance In childhood acute myeloid leukemia on relapse is not higher than at first diagnosis. Pediatric Blood and Cancer, 2004; 42: 195-199.
Drewa T, Styczyński J, Szczepanek J. Is the cancer stem cell population a “player” in multi-drug resistance? Acta Pharm Pol, 2008; 65: 493-500.
Styczyński J, Drewa T. Leukemic stem cells: from metabolic pathways and signaling to new concept of drug resistance targeting. Acta Biochim Pol; 2007; 54: 717-726.
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 286
Number of citations: 0